Gut bacteria of men with confirmed prostate cancer differ significantly from those with benign biopsies, according to data presented at the 2022 Annual European Association of Urology Congress (EAU22) (abstract A0949), in Amsterdam.
The prospective analysis of nearly 200 men undergoing diagnostics for suspected prostate cancer detected notable differences in the gut microbiota profiles of patients who were ultimately diagnosed with the disease compared with those who had benign